and Adcirca (tadalafil; also sold by Eli Lilly as Cialis for erectile dysfunction) tablets. Remodulin is approved for both subcutaneous (SC) and intravenous (IV) use. UTHR sits at a Zacks Rank #3 ...
MarketBeat on MSN18h
Is Eli Lilly a Buy? Analyst Confidence Grows for 2025Eli Lilly’s (NYSE: LLY) market isn’t out of the weeds yet but will rebound strongly in 2025. The Q3 results failed to spark a ...
Derived prices are not provided by exchanges. They are derived by market makers in CFD OTC market and hence prices may not be accurate and may differ from the actual market price, meaning prices ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback